Regulus Therapeutics Inc. (RGLS) |
|
1.47 -0.06 (-3.92%)
|
01-27 16:00 |
|
Open: |
1.5679 |
Pre. Close: |
1.53 |
|
High:
|
1.59 |
Low:
|
1.44 |
|
Volume:
|
64,821 |
Market Cap:
|
25(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:32 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.91 One year: 2.23 |
| Support: |
Support1: 1.29 Support2: 1.08 |
| Resistance: |
Resistance1: 1.63 Resistance2: 1.91 |
| Pivot: |
1.47  |
| Moving Average: |
MA(5): 1.48 MA(20): 1.45
MA(100): 1.6 MA(250): 1.99 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 56.2 %D(3): 61.3 |
| RSI: |
RSI(14): 50.6 |
| 52-week: |
High: 3.7 Low: 0.23 |
| Average Vol(K): |
3-Month: 47 (K) 10-Days: 40 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RGLS ] has closed above bottom band by 48.6%. Bollinger Bands are 48.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.59 - 1.6 |
1.6 - 1.6 |
|
Low:
|
1.42 - 1.43 |
1.43 - 1.44 |
|
Close:
|
1.46 - 1.47 |
1.47 - 1.48 |
|
Company Description |
|
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. |
Headline News |
Fri, 13 Jan 2023
Regulus Reports Inducement Grant Under Nasdaq Listing Rule ... - PR Newswire
Mon, 09 Jan 2023
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics - Yahoo Finance
Mon, 12 Dec 2022
Regulus Therapeutics Announces Resignation of Board Member - PR Newswire
Thu, 10 Nov 2022
Regulus Therapeutics Reports Third Quarter 2022 Financial Results ... - PR Newswire
Thu, 27 Oct 2022
Regulus Therapeutics Announces Poster Presentation at ASN ... - PR Newswire
Mon, 12 Sep 2022
Regulus Therapeutics Announces Positive Topline Safety and ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
17 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
3.6 (%) |
|
% Held by Institutions
|
51.3 (%) |
|
Shares Short
|
233 (K) |
|
Shares Short P.Month
|
285 (K) |
Stock Financials |
|
EPS
|
-0.29 |
|
EPS Est Next Qtl
|
-0.16 |
|
EPS Est This Year
|
-0.96 |
|
EPS Est Next Year
|
-0.41 |
|
Book Value (p.s.)
|
2.35 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-37.2 |
|
Return on Equity (ttm)
|
-83.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-1.06 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.68 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-27 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
-5.22 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.62 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-10-03 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
